18.30
-0.19 (-1.03%)
| Previous Close | 18.49 |
| Open | 18.24 |
| Volume | 231,492 |
| Avg. Volume (3M) | 380,857 |
| Market Cap | 6,497,925,632 |
| Price / Earnings (Forward) | 16.92 |
| Price / Sales | 1.25 |
| Price / Book | 0.990 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Bausch + Lomb Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 0.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caspian Capital Lp | 31 Dec 2025 | 1,999,043 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Citigroup, 14.75%) | Buy |
| Median | 19.00 (3.83%) | |
| Low | 16.00 (Stifel, -12.57%) | Hold |
| Average | 18.83 (2.90%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 17.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Feb 2026 | 20.00 (9.29%) | Buy | 17.99 |
| Barclays | 19 Feb 2026 | 20.00 (9.29%) | Hold | 17.65 |
| Citigroup | 19 Feb 2026 | 21.00 (14.75%) | Buy | 17.65 |
| Stifel | 19 Feb 2026 | 16.00 (-12.57%) | Hold | 17.65 |
| 17 Feb 2026 | 15.00 (-18.03%) | Hold | 17.73 | |
| Wells Fargo | 19 Feb 2026 | 18.00 (-1.64%) | Hold | 17.65 |
| Evercore ISI Group | 05 Jan 2026 | 18.00 (-1.64%) | Hold | 16.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAILEY A ROBERT D | 17.06 | - | 29,200 | 498,152 |
| ELDESSOUKY SAM | 17.06 | - | 8,000 | 136,480 |
| ROSS THOMAS W. SR. | 17.98 | - | 9,000 | 161,820 |
| SAUNDERS BRENT L | 17.06 | - | 29,400 | 501,564 |
| Aggregate Net Quantity | 75,600 | |||
| Aggregate Net Value ($) | 1,298,016 | |||
| Aggregate Avg. Buy ($) | 17.29 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SAUNDERS BRENT L | Officer | 06 Mar 2026 | Buy (+) | 14,700 | 17.06 | 250,782 |
| SAUNDERS BRENT L | Officer | 06 Mar 2026 | Acquired (+) | 14,700 | 17.06 | 250,782 |
| ELDESSOUKY SAM | Officer | 06 Mar 2026 | Buy (+) | 4,000 | 17.06 | 68,240 |
| ELDESSOUKY SAM | Officer | 06 Mar 2026 | Acquired (+) | 4,000 | 17.06 | 68,240 |
| BAILEY A ROBERT D | Officer | 06 Mar 2026 | Buy (+) | 14,600 | 17.06 | 249,076 |
| BAILEY A ROBERT D | Officer | 06 Mar 2026 | Acquired (+) | 14,600 | 17.06 | 249,076 |
| ROSS THOMAS W. SR. | Director | 03 Mar 2026 | Buy (+) | 4,500 | 17.98 | 80,910 |
| ROSS THOMAS W. SR. | Director | 03 Mar 2026 | Acquired (+) | 4,500 | 17.98 | 80,910 |
| Date | Type | Details |
|---|---|---|
| 23 Jan 2026 | Announcement | Bausch Health Provides Update on RED-C Phase 3 Clinical Trials |
| 21 Jan 2026 | Announcement | Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026 |
| 20 Jan 2026 | Announcement | Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 |
| 05 Jan 2026 | Announcement | Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Announcement | Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S. |
| 02 Jan 2026 | Announcement | Bausch + Lomb Completes Refinancing of Outstanding Term B Loans |
| 23 Dec 2025 | Announcement | Bausch Health Announces Final Results and Expiration of Exchange Offers |
| 23 Dec 2025 | Announcement | Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2025 | Announcement | Bausch + Lomb Announces Two Board of Directors Appointments |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |